<DOC>
	<DOCNO>NCT02227576</DOCNO>
	<brief_summary>Chemotherapy use treatment primitive tumor central nervous system particularly important platelet toxicity compare chemotherapy use treatment tumor . Chemotherapy postpone toxicity often due thrombocytopenia ( TP ) . The TP and/or anomaly coagulation , spontaneous ( Rogers , 2004 ) induce ( Gerber , 2006 ) dramatic consequence : - specifically neurological ( intratumoral bleed particularly important neovascularization ) functional aggravation sometimes involvement vital prognosis , - digestive ( Garcia-Rodiguez , 2001 ) patient receive long term treatment corticoid ( potential gastric toxicity ) . The encouraging result EORTC/NCIC trial Stupp ( median survival among patient newly diagnose glioblastoma 14.6 month estimate 5-year survival 9 , 8 % ) , change standard care patient ( Stupp et al. , 2009 ) . Patients newly diagnose , histologically confirm glioblastoma receive radiotherapy ( 2 Gy give 5 day per week 6 week , total 60 Gy ) plus continuous daily Temozolomide ( 75 mg per square meter body-surface area per day , 7 day per week first last day radiotherapy ) , follow six cycle adjuvant Temozolomide ( TMZ ) ( 150 200 mg per square meter 5 day 28-day cycle ) . The Stupp regimen currently treatment reference glioblastoma use basis various clinical study new agent . This study aim evaluate Romiplostim treatment TP secondary initial TMZ chemotherapy glioblastoma .</brief_summary>
	<brief_title>Prevention Thrombocytopenia Glioblastoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>Histological proof newly diagnose glioblastoma , Age : 18 old , Information patient sign consent form , Indication `` Stupp `` protocol ( cerebral focal radiotherapy concomitant TMZ follow adjuvant TMZ 6 cycle ) , Patient grade 3 4 TP Temozolomide chemotherapy , regardless onset TP : completion concomitant RT/CT , adjuvant CT adjuvant CT minimum 2 cycle still plan , Normal initial platelet count ( &gt; 100 000/mm3 ) start Temozolomide RT/CT concomitant phase , Adequate haematological , renal , hepatic function time inclusion visit , ECOG PS 02 ( patient unable walk paralysis wheel chair consider ambulatory evaluation ECOG performance status ) , Life expectancy &gt; 2 month , Patients cover French Health Insurance System , Negative pregnancy test time inclusion visit , If require , effective contraception respect criterion CPMP/ICH/286/95 ( implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner ) . Concomitant radiotherapy ( Romiplostim start completion RT/CT concomitant phase ) , Other malignancy ( prior hx malignancy ) , Any anterior systemic chemotherapy , Any know coagulation disease know haematological disease even resolve . Known hypercoagulate state ( e.g. , factor V Leiden , protein C defiency , protein S deficiency , PT 20201 , antiphospholipid antibody syndromeâ€¦ ) , Prior Romiplostim exposure prior exposure TPO mimetics , History thromboembolic disease &lt; 6 month . Treatment anticoagulant Heparin antivitamin K ( LMWH prophylactic treatment authorize ) , Any hematotoxicity ( anemia , neutropenia ) require EPO GCSF , Other cause Temozolomide interruption ( non haematological toxicity ) , Known hypersensitivity Ecoli derive product , Participation study last 30 day , Refusal give write informed consent , Pregnancy nursing , For men woman childbearing potential : Refusal inability use effective mean contraception , Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial , Persons protect legal regime ( guardianship , trusteeship ) , Patients emergency situation , Patients keep detention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>glioblastoma , thrombocytopenia , temozolomide , chemotherapy</keyword>
</DOC>